Now showing items 1868-1887 of 2862

    • p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib? 

      Noujaim, J; Gonzalez, D; Thway, K; Jones, RL; Judson, I (2016-05)
      Exon 11 KIT mutations are found in a majority of gastrointestinal stromal tumors (GIST) and are usually predictive of response to imatinib, a KIT, PDGFRA and ABL inhibitor. Exon 11 mutations with poor sensitivity to imatinib ...
    • P2.05-042 Development of Thoracic Magnetic Resonance Imaging (MRI) for Radiotherapy Planning 

      Bainbridge, H; Wetscherek, A; Eccles, C; Collins, D; Scurr, E; Leach, M; Koh, D-M; Mcdonald, F (Elsevier BV, 2017-01)
    • P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) 

      Chih-Hsin Yang, J; Ou, S-H; De Petris, L; Gadgeel, S; Gandhi, L; Kim, D-W; Barlesi, F; Govindan, R; Dingemans, A-M; Crinò, L; Léna, H; Popat, S; Ahn, JS; Dansin, E; Golding, S; Bordogna, W; Balas, B; Morcos, PN; Zeaiter, A; Shaw, A (Elsevier BV, 2017-01)
    • P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial) 

      Popat, S; Hughes, L; O'Brien, M; Ahmad, T; Lewanski, C; Dernedde, U; Jankowska, P; Mulatero, C; Shah, R; Hicks, J; Geldart, T; Cominos, M; Gray, G; Spicer, J; Bell, K; Ngai, Y; Hackshaw, A (Elsevier BV, 2017-01)
    • P3.02c-003 TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC 

      Krebs, M; Spicer, J; Steele, N; Talbot, D; Brada, M; Wilson, R; Jones, R; Basu, B; Dawes, J; Parmar, M; Purchase, B; Turner, A; Hall, E; Tovey, H; Banerji, U; Yap, T (Elsevier BV, 2017-01)
    • P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC) 

      Garon, E; Reck, M; Rodríguez-Abreu, D; Robinson, A; Hui, R; Tibor, C; Fülöp, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Turner, D; Stone, J; Rangwala, R; Brahmer, J (Elsevier BV, 2017-01)
    • P3.05-006 Anxiolytic Effect of Acupuncture in a Phase II Study of Acupuncture and Morphine for Dyspnea in Lung Cancer and Mesothelioma 

      Minchom, A; Punwani, R; Filshie, J; Bhosle, J; Nimako, K; Myerson, J; Gunapala, R; Popat, S; O'Brien, M (Elsevier BV, 2017-01)
    • p53 and mdm2 in mantle cell lymphoma in leukemic phase 

      Solenthaler, M; Matutes, E; Brito-Babapulle, V; Morilla, R; Catovsky, D (FERRATA STORTI FOUNDATION, 2002-11)
      Background and Objectives. In mantle cell lymphoma (MCL), abnormalities additional to t(11;14) including those affecting genes involved in the p53 pathway, are important for disease-development and progression. This study ...
    • p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer 

      Kudahetti, S; Fisher, G; Ambroisine, L; Foster, C; Reuter, V; Eastham, J; Moller, H; Kattan, MW; Cooper, CS; Scardino, P; Cuzick, J; Berney, DM; Grp, T-AP (WILEY-BLACKWELL PUBLISHING, INC, 2009-07)
      OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS ...
    • p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells 

      Bhana, S; Hewer, A; Phillips, DH; Lloyd, DR (OXFORD UNIV PRESS, 2008-03)
      Cisplatin is an extremely effective chemotherapeutic agent used for the treatment of testicular and other solid tumours. It induces a variety of structural modifications in DNA, the most abundant being the GpG- and ...
    • p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury 

      Faisal, Amir (AMER PHYSIOLOGICAL SOC, 2010-05)
      Arany I, Faisal A, Clark JS, Vera T, Baliga R, Nagamine Y. p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury. Am J Physiol Renal Physiol 298: F1214-F1221, 2010. First published ...
    • PACE-1, a novel protein that interacts with the C-terminal domain of ezrin. 

      Sullivan, A; Uff, CR; Isacke, CM; Thorne, RF (2003-04)
      The ERM proteins (ezrin, radixin, moesin) together with merlin comprise a subgroup of the band 4.1 superfamily. These proteins act as membrane cytoskeletal linker proteins mediating interactions between the cytoplasmic ...
    • Pain in cancer survivors; filling in the gaps 

      Brown, M; Farquhar-Smith, P (Elsevier BV, 2017-10)
    • Painful testicular metastasis from prostate adenocarcinoma. 

      Lee, KA; Mayer, E; Khoo, V (2017-12-05)
      A 60-year-old man presented with unilateral testicular pain and urinary frequency. His presenting prostate-specific antigen (PSA) was 100 ng/mL, and a biopsy revealed Gleason 4+4 prostate adenocarcinoma. The significance ...
    • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. 

      Southey, MC; Goldgar, DE; Winqvist, R; Pylkäs, K; Couch, F; Tischkowitz, M; Foulkes, WD; Dennis, J; Michailidou, K; van Rensburg, EJ; Heikkinen, T; Nevanlinna, H; Hopper, JL; Dörk, T; Claes, KB; Reis-Filho, J; Teo, ZL; Radice, P; Catucci, I; Peterlongo, P; Tsimiklis, H; Odefrey, FA; Dowty, JG; Schmidt, MK; Broeks, A; Hogervorst, FB; Verhoef, S; Carpenter, J; Clarke, C; Scott, RJ; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Fletcher, O; Johnson, N; Bolla, MK; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Marme, F; Burwinkel, B; Yang, R; Guénel, P; Truong, T; Menegaux, F; Sanchez, M; Bojesen, S; Nielsen, SF; Flyger, H; Benitez, J; Zamora, MP; Perez, JI; Menéndez, P; Anton-Culver, H; Neuhausen, S; Ziogas, A; Clarke, CA; Brenner, H; Arndt, V; Stegmaier, C; Brauch, H; Brüning, T; Ko, YD; Muranen, TA; Aittomäki, K; Blomqvist, C; Bogdanova, NV; Antonenkova, NN; Lindblom, A; Margolin, S; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Spurdle, AB; Investigators, K; Wauters, E; Smeets, D; Beuselinck, B; Floris, G; Chang-Claude, J; Rudolph, A; Seibold, P; Flesch-Janys, D; Olson, JE; Vachon, C; Pankratz, VS; McLean, C; Haiman, CA; Henderson, BE; Schumacher, F; Le Marchand, L; Kristensen, V; Alnæs, GG; Zheng, W; Hunter, DJ; Lindstrom, S; Hankinson, SE; Kraft, P; Andrulis, I; Knight, JA; Glendon, G; Mulligan, AM; Jukkola-Vuorinen, A; Grip, M; Kauppila, S; Devilee, P; Tollenaar, RA; Seynaeve, C; Hollestelle, A; Garcia-Closas, M; Figueroa, J; Chanock, SJ; Lissowska, J; Czene, K; Darabi, H; Eriksson, M; Eccles, DM; Rafiq, S; Tapper, WJ; Gerty, SM; Hooning, MJ; Martens, JW; Collée, JM; Tilanus-Linthorst, M; Hall, P; Li, J; Brand, JS; Humphreys, K; Cox, A; Reed, MW; Luccarini, C; Baynes, C; Dunning, AM; Hamann, U; Torres, D; Ulmer, HU; Rüdiger, T; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Slager, S; Toland, AE; Ambrosone, CB; Yannoukakos, D; Swerdlow, A; Ashworth, A; Orr, N; Jones, M; González-Neira, A; Pita, G; Alonso, MR; Álvarez, N; Herrero, D; Tessier, DC; Vincent, D; Bacot, F; Simard, J; Dumont, M; Soucy, P; Eeles, R; Muir, K; Wiklund, F; Gronberg, H; Schleutker, J; Nordestgaard, BG; Weischer, M; Travis, RC; Neal, D; Donovan, JL; Hamdy, FC; Khaw, KT; Stanford, JL; Blot, WJ; Thibodeau, S; Schaid, DJ; Kelley, JL; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Butterbach, K; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Kote-Jarai, Z; Olama, AA; Benlloch, S; Renner, SP; Hartmann, A; Hein, A; Ruebner, M; Lambrechts, D; Van Nieuwenhuysen, E; Vergote, I; Lambretchs, S; Doherty, JA; Rossing, MA; Nickels, S; Eilber, U; Wang-Gohrke, S; Odunsi, K; Sucheston-Campbell, LE; Friel, G; Lurie, G; Killeen, JL; Wilkens, LR; Goodman, MT; Runnebaum, I; Hillemanns, PA; Pelttari, LM; Butzow, R; Modugno, F; Edwards, RP; Ness, RB; Moysich, KB; du Bois, A; Heitz, F; Harter, P; Kommoss, S; Karlan, BY; Walsh, C; Lester, J; Jensen, A; Kjaer, SK; Høgdall, E; Peissel, B; Bonanni, B; Bernard, L; Goode, EL; Fridley, BL; Vierkant, RA; Cunningham, JM; Larson, MC; Fogarty, ZC; Kalli, KR; Liang, D; Lu, KH; Hildebrandt, MA; Wu, X; Levine, DA; Dao, F; Bisogna, M; Berchuck, A; Iversen, ES; Marks, JR; Akushevich, L; Cramer, DW; Schildkraut, J; Terry, KL; Poole, EM; Stampfer, M; Tworoger, SS; Bandera, EV; Orlow, I; Olson, SH; Bjorge, L; Salvesen, HB; van Altena, AM; Aben, KK; Kiemeney, LA; Massuger, LF; Pejovic, T; Bean, Y; Brooks-Wilson, A; Kelemen, LE; Cook, LS; Le, ND; Górski, B; Gronwald, J; Menkiszak, J; Høgdall, CK; Lundvall, L; Nedergaard, L; Engelholm, SA; Dicks, E; Tyrer, J; Campbell, I; McNeish, I; Paul, J; Siddiqui, N; Glasspool, R; Whittemore, AS; Rothstein, JH; McGuire, V; Sieh, W; Cai, H; Shu, XO; Teten, RT; Sutphen, R; McLaughlin, JR; Narod, SA; Phelan, CM; Monteiro, AN; Fenstermacher, D; Lin, HY; Permuth, JB; Sellers, TA; Chen, YA; Tsai, YY; Chen, Z; Gentry-Maharaj, A; Gayther, SA; Ramus, SJ; Menon, U; Wu, AH; Pearce, CL; Van Den Berg, D; Pike, MC; Dansonka-Mieszkowska, A; Plisiecka-Halasa, J; Moes-Sosnowska, J; Kupryjanczyk, J; Pharoah, PD; Song, H; Winship, I; Chenevix-Trench, G; Giles, GG; Tavtigian, SV; Easton, DF; Milne, RL (2016-09-05)
      The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated ...
    • Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. 

      Loibl, S; Turner, NC; Ro, J; Cristofanilli, M; Iwata, H; Im, S-A; Masuda, N; Loi, S; André, F; Harbeck, N; Verma, S; Folkerd, E; Puyana Theall, K; Hoffman, J; Zhang, K; Bartlett, CH; Dowsett, M (2017-09)
      BACKGROUND: The efficacy and safety of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, combined with fulvestrant and goserelin was assessed in premenopausal women with advanced breast cancer (ABC) who had progressed ...
    • Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). 

      Verma, S; Bartlett, CH; Schnell, P; DeMichele, AM; Loi, S; Ro, J; Colleoni, M; Iwata, H; Harbeck, N; Cristofanilli, M; Zhang, K; Thiele, A; Turner, NC; Rugo, HS (2016-07)
      Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, ...
    • A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. 

      Prat, A; Lluch, A; Turnbull, AK; Dunbier, AK; Calvo, L; Albanell, J; de la Haba-Rodríguez, J; Arcusa, A; Chacón, JI; Sánchez-Rovira, P; Plazaola, A; Muñoz, M; Paré, L; Parker, JS; Ribelles, N; Jimenez, B; Bin Aiderus, AA; Caballero, R; Adamo, B; Dowsett, M; Carrasco, E; Martín, M; Dixon, JM; Perou, CM; Alba, E (2017-06-15)
      Purpose: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.Experimental Design: Research-based ...
    • Pan-cancer analysis of the extent and consequences of intratumor heterogeneity 

      Andor, N; Graham, TA; Jansen, M; Xia, LC; Aktipis, CA; Petritsch, C; Ji, HP; Maley, CC (NATURE PUBLISHING GROUP, 2016-01)
      Intratumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used the bioinformatics tools ‘expanding ploidy and allele frequency on nested subpopulations’ (EXPANDS) and PyClone to detect ...
    • PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. 

      Sclafani, F; Brown, G; Cunningham, D; Wotherspoon, A; Tait, D; Peckitt, C; Evans, J; Yu, S; Sena Teixeira Mendes, L; Tabernero, J; Glimelius, B; Cervantes, A; Thomas, J; Begum, R; Oates, J; Chau, I (2016-08)
      EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC).We pooled individual patient data from these ...